E-LIB Suche - Ergebnisse für: Tsukamoto, Yuko

1

Population Pharmacokinetics of Paliperidone Palmitate (Once..:

Shimizu, Hiroko ; Neyens, Martine ; De Meulder, Marc...
Clinical Pharmacology in Drug Development. 9 (2019) 2 - p. 224-234 , 2019

Link: https://doi.org/10.1002/..

2

Cilostazol protects against microvascular brain injury in a..:

Tsukamoto, Yuko ; Nagata, Eiichiro ; Fukuyama, Naoto...
Neuroscience Research. 117 (2017) - p. 48-53 , 2017

Link: https://doi.org/10.1016/..

3

Altered blood flow in cerebral perforating arteries of rat ..:

Fukuyama, Naoto ; Tsukamoto, Yuko ; Takizawa, Shunya...
Geriatrics & Gerontology International. 15 (2015) - p. 74-80 , 2015

Link: https://doi.org/10.1111/..

4

Pharmacokinetics and safety of sirukumab following a single..:

Zhuang, Yanli ; Xu, Zhenhua ; Vries, Dick E. de...
Int. Journal of Clinical Pharmacology and Therapeutics. 51 (2013) 3 - p. 187-199 , 2013

Link: https://doi.org/10.5414/..

5

Should Clinical Pharmacokinetic Bridging Studies Between Ca..:

Zhou, Honghui ; Tsukamoto, Yuko ; Davis, Hugh M.
The Journal of Clinical Pharmacology. 52 (2012) 8 - p. 1273-1276 , 2012

Link: https://doi.org/10.1177/..

6

Lack of an Effect of Madopar on the Disposition of Tolcapon..:

Funaki, Tomoo ; Onodera, Hideko ; Ushiyama, Naomi...
Journal of Pharmacy and Pharmacology. 47 (2011) 6 - p. 539-542 , 2011

Link: https://doi.org/10.1111/..

7

The Disposition of the Tolcapone 3-O-Methylated Metabolite ..:

Funaki, Tomoo ; Onodera, Hideko ; Ushiyama, Naomi...
Journal of Pharmacy and Pharmacology. 46 (2011) 7 - p. 571-574 , 2011

Link: https://doi.org/10.1111/..

8

A mechanism‐based binding model for the population pharmaco..:

Hayashi, Naoto ; Tsukamoto, Yuko ; Sallas, William M..
British Journal of Clinical Pharmacology. 63 (2007) 5 - p. 548-561 , 2007

Link: https://doi.org/10.1111/..

9

Clinical Pharmacokinetic/Pharmacodynamic and Physiologicall..:

Blesch, Karen S. ; Gieschke, Ronald ; Tsukamoto, Yuko...
Investigational New Drugs. 21 (2003) 2 - p. 195-223 , 2003

Link: https://doi.org/10.1023/..

10

The Intestinal First-pass Metabolism of Substrates of CYP3A..:

Kato, Motohiro ; Chiba, Koji ; Hisaka, Akihiro...
Drug Metabolism and Pharmacokinetics. 18 (2003) 6 - p. 365-372 , 2003

Link: https://doi.org/10.2133/..

11

Which concentration of the inhibitor should be used to pred..:

Ito, Kiyomi ; Chiba, Koji ; Horikawa, Masato...
AAPS PharmSci. 4 (2002) 4 - p. 53-60 , 2002

Link: https://doi.org/10.1208/..

12

Investigation of 5‐FU disposition after oral administration..:

Tsukamoto, Yuko ; Kato, Yukio ; Ura, Masako...
Biopharmaceutics & Drug Disposition. 22 (2001) 1 - p. 1-14 , 2001

Link: https://doi.org/10.1002/..

13

Effects of the catechol-O-methyltransferase inhibitor tolca..:

Tohgi, Hideo ; Abe, Takashi ; Yamazaki, Kinya...
Neuroscience Letters. 192 (1995) 3 - p. 165-168 , 1995

Link: https://doi.org/10.1016/..

14

Population Pharmacokinetics of Paliperidone Palmitate (Once..:

Shimizu, Hiroko ; Neyens, Martine ; De Meulder, Marc...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028061/. , 2019

Link: http://www.ncbi.nlm.nih...

15

A mechanism-based binding model for the population pharmaco..:

Hayashi, Naoto ; Tsukamoto, Yuko ; Sallas, William M.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000760. , 2007

Link: http://www.ncbi.nlm.nih...